Spero outlines cash runway into the second half of 2029 following $105M royalty financing (NASDAQ:SPRO)
· seekingalpha.com
Spero Therapeutics (SPRO) Q2 2026 earnings call highlights: FDA approval of Utebzi, SP001 licensing, $105M royalty financing, runway to 2029—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...